TIDMOPTI

RNS Number : 8468W

OptiBiotix Health PLC

24 April 2019

OptiBiotix Health plc

("OptiBiotix")

SlimBiome(R) Medical launches in UK market

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces the launch of its innovative weight management solution SlimBiome(R) Medical to the UK market.

SlimBiome(R) Medical, which is a CE marked medical device, offers a healthy, hunger-free weight management solution designed for use by itself, or as part of a calorie-restricted diet, to reduce hunger and help users achieve sustainable weight loss. Independent clinical studies show SlimBiome(R) reduces hunger, cravings for sweet and savoury foods, and fat intake. It will be available in boxes of 30 single dose sachets and for purchase from the OptiBiotix Online store (Optibiotix.online) from 29 April 2019.

This commercial launch follows on from the announcement that SlimBiome(R) was granted medical device status and a CE mark (RNS: 27 November 2018), the appointment of Nutrilinea S.R.L as a manufacturer (RNS: 29 November 2018), and three year distribution agreements for Greece and Cyprus (RNS: 4 December 2018) and Bulgaria (RNS: 9 April 2019).

OptiBiotix is also pleased to report prelaunch sales of SlimBiome(R) Medical to Bridge4 Health Ltd, a unique health and well-being centre based in Leicester. Bridge4 Health will conduct a three month SlimBiome(R) Medical field trial involving its gym members to support healthy sustained weight loss. These early deals and sales orders so soon after achieving medical device registration reflect the high level of interest we have received in SlimBiome(R) Medical from an industry which recognises the value of products with strong science and published human studies.

The online sale of SlimBiome(R) Medical as a final product is another example of OptiBiotix's strategy of building multiple revenue streams from ingredient sales, white label and own label branded consumer products, across multiple sales channels. It provides a new route to market for SlimBiome(R) allowing the company to generate immediate revenues while building sales with international and retail partners from SlimBome(R) as an ingredient, medical device, and in white label or branded GoFigure final products. We anticipate further commercial agreements for SlimBiome(R), SlimBiome(R) Medical, and GoFigure products in international markets in the months ahead.

Fred Narbel, Managing Director of the Prebiotics division, commented: "SlimBiome(R) Medical is a innovative product transforming the way weight loss is traditionally approached as it delivers a sustainable, science-backed weight control system which offers dieters additional support to sustain and/or maintain weight loss. We are delighted to be able to bring this product to the UK market through our online store which allows us to build early revenues at high margin through direct to consumer sales."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                                         www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                             Contact via Walbrook 
                                                                                            below 
 
 Cairn Financial Advisers LLP (NOMAD)                                          Tel: 020 7213 0880 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                              Tel: 020 7220 0500 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                                  Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                                                   Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PRLGMGZDKFFGLZM

(END) Dow Jones Newswires

April 24, 2019 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Optibiotix Health.
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Optibiotix Health.